The Cohort for Patient-reported Outcomes, Imaging and Trial Inclusion in Metastatic BRAin Disease (COIMBRA)

Launched by UMC UTRECHT · Feb 23, 2022

Keywords

ClinConnect Summary

The COIMBRA trial is studying new ways to treat brain metastases, which are cancer cells that have spread to the brain from other parts of the body. As treatments for other cancers improve, more patients are facing this condition, and it's important to find effective ways to manage it. This trial uses a special research design called a "cohort multiple Randomized Controlled Trial," which allows for quicker testing of new treatments and aims to improve how we deliver care to patients over time.

To participate in the trial, you need to be at least 18 years old and have confirmed metastatic brain disease or be eligible for a specific type of preventive radiation therapy called prophylactic cranial irradiation. The trial is currently looking for participants, and those who join can expect to receive care from a team of professionals while contributing to important research. However, people with severe mental health issues or difficulties understanding the study details might not be eligible. If you or a loved one is considering joining this trial, it could be an opportunity to help advance treatment for this challenging condition.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Age ≥ 18 years;
• • Either radiographic and/or histologic proof of metastatic brain disease, or eligible for prophylactic cranial irradiation;
• • Referred to the Department of Radiotherapy for cranial irradiation.
• Exclusion Criteria:
• • Mental disorder or cognitive dysfunction that hinder the patient's ability to understand the informed consent procedure and/or study details;
• • Patients with severe psychiatric disorders;
• • Inability to understand the Dutch language.